Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265122 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
A Phase 2 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT00265122 is a Phase 2 study that has completed, run by Centocor. The registered enrollment target is 131 participants.
The verdict
NCT00265122, a Phase 2 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.
Interventions
- DRUG Placebo IV
- DRUG Placebo SC
- DRUG Ustekinumab 90 mg
- DRUG Ustekinumab 4.5 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265122
The ClinicalTrials.gov registry entry for NCT00265122 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo IV is the first listed.
NCT00265122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265122 about?
NCT00265122 is a clinical study titled "A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease". The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.
What is the current status of trial NCT00265122?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2004-04. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00265122?
The interventions under investigation include: Placebo IV (DRUG), Placebo SC (DRUG), Ustekinumab 90 mg (DRUG), Ustekinumab 4.5 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00265122?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.